Close Menu
    Facebook X (Twitter) Instagram
    Latest
    • A new malpractice being observed: Reviewers asking their own papers to cite
    • 100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    • Retraction Notice: Pharmacological Actions of Impatiens
    • DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    • IGJPS, 2021, Vol 11, Issue 3
    • IGJPS, 2021, Vol 11, Issue 2
    • IGJPS, 2021, Vol 11, Issue 1
    • Table of Contents, Vol 10, Issue 4
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    • Home
    • About Us
    • Issues
      • IGJPS 2022 and Onwards
      • IGJPS, 2021, Vol 11, Issue 3
      • IGJPS, 2021, Vol 11, Issue 2
      • IGJPS, 2021, Vol 11, Issue 1
      • IGJPS, 2020, Vol 10, Issue 4
      • IGJPS, 2020, Vol 10, Issue 3
      • IGJPS, 2020, Vol 10, Issue 2
      • IGJPS, 2020, Vol 10, Issue 1
      • IGJPS, 2019, Vol 9, Issue 2 (Suppl.)
      • IGJPS, 2019, Vol 9, Issue 2
      • IGJPS, 2019, Vol 9, Issue 1
      • IGJPS, 2018, Vol 8, Issue 3
      • IGJPS, 2018, Vol 8, Issue 2
      • IGJPS, 2018, Vol 8, Issue 1
      • IGJPS, 2017, Vol 7, Issue 2
      • IGJPS, 2017, Vol 7, Issue 1
      • IGJPS, 2016, Vol 6, Issue 2
      • IGJPS, 2016, Vol 6, Issue 1
      • IGJPS, 2015, Vol 5, Issue 3
      • IGJPS, 2015, Vol 5, Issue 2
      • IGJPS, 2015, Vol 5, Issue 1
      • IGJPS, 2014, Vol 4, Issue 3
      • IGJPS, 2014, Vol 4, Issue 2
      • IGJPS, 2014, Vol4, Issue 1
      • IGJPS, 2013, Vol 3, Issue 3
      • IGJPS,2013, Vol 3, Issue 2
      • IGJPS, 2013, Vol 3, Issue 1
      • IGJPS, 2012, Vol 2, Issue 4
      • IGJPS, 2012, Vol 2, Issue 3
      • IGJPS, 2012, Vol 2, Issue 2
      • IGJPS, 2012, Vol 2, Issue 1
      • IGJPS, 2011, Vol 1, Issue 4
      • IGJPS, 2011, Vol 1, Issue 3
      • IGJPS, 2011, Vol 1, Issue 2
      • IGJPS, 2011, Vol 1, Issue 1
    • Editorial Board
    • Guidelines For Authors
    • Indexed
    • Manuscript Submission
    • Contact Us
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    You are at:Home»News»Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients

    Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients

    0
    By Rajeev Singla on January 21, 2012 News

    Bristol-Myers Squibb Company (NYSE: BMY) announced a donation of $6.9 million in 2011 to support the HealthWell Foundation, an independent non-profit organization that provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. The donation was made to HealthWell’s co-pay assistance funds to help underinsured cancer patients with their out-of-pocket disease related expenses that are not covered by their insurance plans, regardless of treatment selected.

    “Bristol-Myers Squibb has robust patient assistance programs for cancer patients and this contribution reinforces our commitment to helping patients gain access to the medicines they need,” said John Tsai, vice president, U.S. Medical, Bristol-Myers Squibb. “We are proud to support the HealthWell Foundation in its mission to reduce barriers to care for underinsured patients.”

    In addition to its support of cancer patients, Bristol-Myers Squibb has a number of patient assistance programs in place in other disease areas for eligible patients. In 2011, the company helped more than 200,000 patients with free Bristol-Myers Squibb prescription medications estimated at more than $400 million through donations to the Bristol-Myers Squibb Patient Assistance Foundation as well as other programs.

    About Bristol-Myers Squibb
    Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

     

    Source- World Pharma News

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    A new malpractice being observed: Reviewers asking their own papers to cite

    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life

    Retraction Notice: Pharmacological Actions of Impatiens

    Comments are closed.

    Latest News
    A new malpractice being observed: Reviewers asking their own papers to cite
    ...
    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    ...
    Retraction Notice: Pharmacological Actions of Impatiens
    ...
    DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    ...
    Top Peer Reviewer as New Associate Editor: Dr. Ghulam Md. Ashraf, King Abdulaziz University, Jeddah, Saudi Arabia
    ...
    Highly Cited Articles

    Microencapsulation–A Novel Approach in Drug Delivery: A Review

    Review on the pharmacognostical & pharmacological characterization of Apium graveolens Linn


    Medicinal Plants of Rural India: A Review of Use by Indian Folks


    Self Emulsifying Drug Delivery System: A Tool in Solubility Enhancement of Poorly Soluble Drugs


    Antioxidant and antimicrobial activities of Cocos nucifera Linn.(Arecaceae) endocarp extracts

    Impotant Links
    • About Us
    • Call For Papers
    • Contact Us
    • Editorial Board
    • For Reviewers
    • Guidelines For Authors
    • Home Page
    • Indexed
    • Issues
    • Manuscript Submission
    • Checkout
    • Transaction Results
    • Your Account
    Sponsored
    Copyright © 2011 iGlobal Research & Publishing Foundation
    Powered By :- Ganga Graphix.

    Type above and press Enter to search. Press Esc to cancel.